Hematology

IDEXX launches groundbreaking new ProCyte One Hematology Analyzer with dramatically simplified user experience

Wednesday, August 12, 2020 - 12:30pm

"ProCyte One reimagines point-of-care hematology with a radically simple workflow that virtually eliminates complexity without sacrificing performance," said Jay Mazelsky, President and Chief Executive Officer of IDEXX Laboratories.

Key Points: 
  • "ProCyte One reimagines point-of-care hematology with a radically simple workflow that virtually eliminates complexity without sacrificing performance," said Jay Mazelsky, President and Chief Executive Officer of IDEXX Laboratories.
  • Packed with leading-edge technology and artificial intelligence, the ProCyte One Hematology Analyzer transforms point-of-care hematology with:
    Reference laboratory-quality results, bringing added confidence to clinical decision-making.
  • The IDEXX Hematology portfolio, including the ProCyte One analyzer, ProCyte Dx analyzer, and IDEXX Reference Laboratories' CBC testing, offers the most accurate and comprehensive CBC testing available.
  • The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties.

IDEXX launches groundbreaking new ProCyte One Hematology Analyzer with dramatically simplified user experience

Wednesday, August 12, 2020 - 12:30pm

"ProCyte One reimagines point-of-care hematology with a radically simple workflow that virtually eliminates complexity without sacrificing performance," said Jay Mazelsky, President and Chief Executive Officer of IDEXX Laboratories.

Key Points: 
  • "ProCyte One reimagines point-of-care hematology with a radically simple workflow that virtually eliminates complexity without sacrificing performance," said Jay Mazelsky, President and Chief Executive Officer of IDEXX Laboratories.
  • Packed with leading-edge technology and artificial intelligence, the ProCyte One Hematology Analyzer transforms point-of-care hematology with:
    Reference laboratory-quality results, bringing added confidence to clinical decision-making.
  • The IDEXX Hematology portfolio, including the ProCyte One analyzer, ProCyte Dx analyzer, and IDEXX Reference Laboratories' CBC testing, offers the most accurate and comprehensive CBC testing available.
  • The reports filed by IDEXX pursuant to United States securities laws contain discussions of some of these risks and uncertainties.

Wyatt Law Firm, Carabin Shaw Partner To Help COVID-19 Patients

Monday, August 10, 2020 - 10:29pm

SAN ANTONIO, Aug. 10, 2020 /PRNewswire/ --San Antonio-area law firms Wyatt Law Firm, PLLC, and Carabin Shaw are partnering to assist the South Texas Blood & Tissue Center's (STBTC) efforts to collect convalescent plasma for COVID-19 patients.

Key Points: 
  • SAN ANTONIO, Aug. 10, 2020 /PRNewswire/ --San Antonio-area law firms Wyatt Law Firm, PLLC, and Carabin Shaw are partnering to assist the South Texas Blood & Tissue Center's (STBTC) efforts to collect convalescent plasma for COVID-19 patients.
  • The plasma is used to treat patients with active infections, and it is one of the few treatments available for COVID-19.
  • "The fight isn't over, so we need to continue to collect plasma from recovered COVID-19 patients," said Paula Wyatt, Founding Partner of Wyatt Law Firm.
  • "We felt it was vital for us to encourage people to make a lifesaving plasma donation," said Jamie Shaw, a partner at Carabin Shaw.

Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome

Monday, August 10, 2020 - 12:30pm

Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today reported the results of a compassionate-use study evaluating narsoplimab, Omeros investigational human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), in the treatment of COVID-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe and life-threatening symptom of COVID-19.
  • Narsoplimab also has been evaluated in patients in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), another often-lethal thrombotic disorder associated with endothelial damage.
  • In its pivotal HSCT-TMA trial, narsoplimab-treated patients demonstrated marked improvement in laboratory and clinical endpoints and unexpected survival.
  • Omeros management will host a webcast and conference call to present the results of a compassionate-use study evaluating narsoplimab in the treatment of COVID-19 patients with ARDS.

Cerus INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch

Friday, August 7, 2020 - 1:30pm

Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma doses globally since commercial launch.
  • We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.
  • The INTERCEPT Blood System for platelets and plasma provides a proactive approach to reduce the risk of transfusion-transmitted infectious disease (TTID).
  • INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Haemonetics Clinical Study Results On A New, Personalized Approach To Plasma Collection To Be Presented At 2020 AABB Annual Meeting

Friday, August 7, 2020 - 11:45am

The IMPACT study, one of the largest clinical trials on the topic of plasmapheresis, was designed to test a novel, personalized approach to plasma collection using the NexSys PCS Plasma Collection System.

Key Points: 
  • The IMPACT study, one of the largest clinical trials on the topic of plasmapheresis, was designed to test a novel, personalized approach to plasma collection using the NexSys PCS Plasma Collection System.
  • The IMPACT study was a multicenter, prospective, double-blinded, randomized controlled clinical trial involving 3,443 donors who underwent 23,137 plasma donations.
  • The number of repeat donations was not impacted and increasing collection volume up to 1,000 mL was well tolerated.
  • "At a time when the world needs more plasma, this trial shows the value of a personalized approach."

BioLife Plasma Services Announces Opening of First Plasma Collection Center in Louisiana

Thursday, August 6, 2020 - 5:01pm

BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.

Key Points: 
  • BioLife Plasma Services, part of the global biopharmaceutical company Takeda Pharmaceutical Company Limited, today announced the opening of a new plasma collection center in Baton Rouge to collect standard plasma from healthy donors.
  • Plasma is a lifeline for thousands of people with rare, chronic and complex diseases, and we are excited to open the first BioLife plasma collection center in Louisiana.
  • To learn more about BioLife Plasma Services, the donation process, and to schedule an appointment, please visit the BioLife website.
  • BioLife Plasma Services is an industry leader in the collection of high-quality plasma that is processed into life-saving plasma-based therapies.

$990M HLA Typing Market by Product, Technology, Application, End-user and Geography - Forecast to 2026 - ResearchAndMarkets.com

Wednesday, August 5, 2020 - 1:53pm

The "HLA Typing Market by Product, by Technology, by Application, by End-Users, Geography Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HLA Typing Market by Product, by Technology, by Application, by End-Users, Geography Forecast up to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global HLA typing market is expected to reach USD 990.12 million by 2026 from USD 659.75 million in 2020, rising at a CAGR of ~7%.
  • Majorly the increase in certain diseases such as blood cancers, genetic blood disorders where stem cell transplantation is required, this situation is expected to drive the HLA Typing market.
  • Globally, the HLA Typing market is growing at a CAGR of ~7.0% during the forecast period of 2020-2026.

Doctors Uncover COVID-19 Connections to Blood Clots, Dementia Using Epic

Tuesday, August 4, 2020 - 12:10pm

Doctors are looking for answers to questions like, "Is COVID-19 causing blood clots?"

Key Points: 
  • Doctors are looking for answers to questions like, "Is COVID-19 causing blood clots?"
  • or "Is there a link between dementia and COVID-19?"
  • A graph instantly confirmed their suspicions: otherwise healthy patients with COVID-19 were three times more likely to develop blood clots.
  • At Mount Sinai Health System in New York, clinicians using SlicerDicer were among the first in the world to discover a connection between dementia and COVID-19 severity.

Autolus announces changes to its Board and Management Team

Tuesday, August 4, 2020 - 12:00pm

Dr. Vijay Peddareddigari, Senior Vice President, Chief Medical Officer, is leaving the Company to return to the US.

Key Points: 
  • Dr. Vijay Peddareddigari, Senior Vice President, Chief Medical Officer, is leaving the Company to return to the US.
  • We are delighted with Dr. Jay Backstroms appointment to the Board of Directors.
  • I would also like to thank Vijay for his significant contributions to Autolus and wish him well in his future endeavors.
  • Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.